SAN FRANCISCO, CA — May 23, 2002 — Family histories are often incomplete despite their importance in helping determine who to screen for colorectal cancers.
ORLANDO, FL — May 23, 2002 — Treatment with the radiolabeled monoclonal antibody ibritumomab tiuxetan (Zevalin) preserves sensitivity to subsequent therapy with rituximab in at
ORLANDO, FL — May 23, 2002 — Adding the HER2 antagonist trastuzumab to a neoadjuvant treatment regimen with docetaxel and cisplatin results in node-free presurgery
ORLANDO, FL — May 23, 2002 — Schering-Plough Research Institute (SPRI) reported results from several early phase clinical trials of the oral farnesyl transferase inhibitor
ORLANDO, FL — May 20, 2002 — Interim analyses suggest that imatinib is an effective treatment for interferon-resistant chronic phase chronic myelogenous leukemia (CML). The
ORLANDO, FL — May 20, 2002 — To achieve maximum benefit, adjuvant tamoxifen therapy should be initiated after completion of adjuvant chemotherapy for treatment of
ORLANDO, FL — May 20, 2002 — Adding target therapy with the investigational anticancer antibody C225 (Erbitux) to standard cisplatin chemotherapy appears to increase the
ORLANDO, FL — May 20, 2002 — Patients who received a docetaxel-based treatment for adjuvant therapy of node positive breast cancer rather than a 5-flourouracil-based
05/20/2002 By Elda Hauschildt Patients with early invasive cervical adenocarcinoma to a depth of three millimetres or less stromal invasion can be treated with non-radical
05/20/2002 By David Ball Transplantation and/or ablation might offer alternative treatments in patients least likely to benefit from resection for small hepatocellular cancers (HCCs). Such
Laurie Barclay, MD NEW YORK (MedscapeWire) May 20 The new radioimmunotherapy drug ibritumomab (Zevalin) looks promising for treating low-grade B-cell non-Hodgkin’s lymphoma, according to
International Journal of Radiation Oncology, Biology and Physics (IJROBP Online) 05/16/2002 By Elda Hauschildt Radiation doses that seem safe in breast cancer patients, even at
LONDON (Reuters Health) May 16 – Patients with preoperative hemoglobin concentrations of 100 g/L or less are at increased risk for death after coronary artery
NEW YORK (Reuters Health) May 14 – In diabetics at high-risk for pancreatic cancer, there appears to be a 3-year period following diagnosis that is
NEW YORK (Reuters Health) Apr 30 – Despite good control of the disease, patients treated for early-stage Hodgkin's disease have a sustained risk of excess
Laurie Barclay, MD NEW YORK (MedscapeWire) May 01 Four studies presented April 29-30 at the American Roentgen Ray Society annual meeting in Atlanta, Georgia,
Xeloda combination extends breast cancer survival and becomes a new standard of care LONDON, ENGLAND — May 1, 2002 — Roche announced that the European
Laurie Barclay, MD NEW YORK (MedscapeWire) May 01 In patients with increasing prostate specific antigen (PSA) levels after prostatectomy, magnetic resonance imaging (MRI) can
CHAPEL HILL, NC — April 26, 2002 — Long-term survival results from a breast cancer treatment study begun in 1992 at the University of North
NEW YORK (Reuters Health) Apr 25 – Tumor metastasis takes place by way of lymphatic vessels at the tumor margins, without the need for functional